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Background. DB289 is the orally active prodrug of the
diamidine DB75, which was developed for the treatment of
human African trypanosomiasis.
Methods. We tested the safety and efficacy of DB289 for
the treatment of Plasmodium vivax and acute, uncomplicat-
ed P. falciparum infections in an open-label pilot study at the
Hospital for Tropical Diseases in Bangkok. Nine patients with
P. vivax infections and 23 patients with P. falciparum infections
were admitted and treated with 100 mg of DB289 given orally
twice a day for 5 days and were followed for 28 days. Patients
with P. vivax infections were also treated with primaquine on
days 10–23.
Results. All patients cleared parasites by day 7, with a
clearance time of h. One patient with amean SD 43 41
P. vivax infection had a recurrence of parasitemia on day 9. Of
the 23 patients with P. falciparum infections, 3 had recurrences
of parasitemia caused by P. vivax and 2 had recurrences of
parasitemia caused by P. falciparum. In only 1 of 2 recurrences
of parasitemia caused by P. falciparum were the parasites ge-
notypically distinct from the infecting parasites the patient had
at enrollment, which means there was a 96% cure rate.
Conclusions. DB289 is a promising new antimalarial com-
pound that could become an important component of new an-
timalarial combinations.
Cross-resistance represents a major impediment in the devel-
opment of new antimalarial compounds. Many antimalarial com-
pounds under development are structurally related to existing
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ones and are likely to encounter cross-resistance. Thus, new
classes of antimalarial compounds are needed. One such novel
class is the diamidines. Although results of preliminary studies
have shown that diamidines such as pentamidine have in vitro
activity against Plasmodium falciparum [1], they have never
been used to treat malaria. Pentamidine and other older diam-
idines are toxic and very poorly absorbed after oral adminis-
tration [2]. Newer diamidines that are far less toxic and are
orally bioavailable have been synthesized [3].
The 2,5-bis(4-amidinophenyl)furan DB75 is a new diamidine
with excellent broad-spectrum antimicrobial activity—against
Plasmodium species, Trypanosoma brucei, Pneumocystis jiroveci,
Cryptosporidium parvum, and other pathogens—when admin-
istered systemically. DB75 is active in vitro against chloroquine-
sensitive and chloroquine-resistant strains of P. falciparum.
DB75 given subcutaneously or intravenously for 4 days is active
against Plasmodium berghei and Plasmodium chabaudi infec-
tions (R.B., unpublished data).
DB289, the diamidoxime derivative of DB75, acts as an oral-
ly bioavailable prodrug that is readily metabolized to the active
aromatic dication [4]. Phase 1 clinical studies demonstrated that
DB289 is rapidly metabolized to DB75 in humans and that a
twice daily regimen of oral DB289 will sustain DB75 plasma
levels above the target antimicrobial level [5]. In phase 2 clinical
trials of DB289 against P. jiroveci pneumonia and human African
trypanosomiasis, no serious adverse events were noted [3].
Patients, materials, and methods. Patients with Plasmodium
vivax infections and acute, uncomplicated P. falciparum infec-
tions were enrolled between August and November 2003, in an
open-label, phase 2 trial to evaluate the efficacy, safety, tolerance,
and pharmacokinetics of DB289 at the Hospital for Tropical
Diseases, Mahidol University, Bangkok. Patients came to the hos-
pital from nearby rural regions of Thailand that had low levels
of transmission of malaria [6]. The study was approved by the
Mahidol University Institutional Ethics Committee and the Eth-
ics Committee of the Thai Ministry of Public Health.
Written, informed consent was obtained from each patient.
We enrolled male and female patients, 18 years old, who had
a minimum body weight of 35 kg. Patients were included in the
study if they had !25,000 parasites/mL of blood and had either
a single-species infection with an asexual form of P. vivax that
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was confirmed by peripheral blood smear or an acute, uncom-
plicated, single-species infection with an asexual form of P. falcip-
arum that was confirmed by peripheral blood smear. Women of
childbearing potential were included if they were not lactating,
had a negative result for a urine test for pregnancy within 24 h
before treatment with DB289, and agreed to use a valid method
of contraception from the day of consent until 7 days after the
completion of treatment with DB289 (study day 12). Not all
patients were febrile at enrollment. Patients who required par-
enteral treatment, had severe organ dysfunction, or had been
exposed to antimalarial compounds within 3 days (or to meflo-
quine within 5 days) before enrollment were excluded. Patients
with severe malaria (according to the 2000 World Health Or-
ganization criteria), a history of drug hypersensitivity or allergies,
chronic heart disease or clinically relevant abnormalities on an
electrocardiogram, psychiatric disorders, a glucose-6-phosphate
dehydrogenase deficiency, or other laboratory test results that
deviated from baseline levels were also excluded.
All patients were treated with 100 mg of DB289 given orally
twice a day from day 1 to day 5. DB289 gelcaps (100 mg) were
provided by Immtech International. Primaquine (15 mg/kg/day
for 14 days; Government Pharmaceutical Organization of Thai-
land) was administered to patients on days 10–23 for the treat-
ment of hypnozoite-stage P. vivax infections. No other drugs
that have antimalarial activity were given to patients until com-
pletion of the study or relapse. Patients were maintained in the
hospital for observation during treatment and for no less than
5 days after the completion of treatment. Blood smears were
taken every 12 h until patients were free of parasites, daily to
day 7, and on days 10, 14, 21, and 28. Parasite counts were
done from Giemsa-stained thick and thin films. Any patient
who had a treatment failure after treatment with DB289 re-
ceived the standard of care at the site: artesunate with meflo-
quine or chloroquine with primaquine, as appropriate.
The following analyses were performed on blood or serum
from all patients on days 0, 3, 7, 10, 21, and 28: complete and
differential blood count, hemoglobin concentration, measure-
ment of prothrombin and activated partial thromboplastin
time, and measurement of levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), alkaline phosphatase,
glucose, total bilirubin, total protein, albumin, sodium, potas-
sium, chloride, creatinine, blood urea nitrogen, and amylase.
Urine tests to measure the pH level, glucose level, and ketone
levels and to detect the presence of protein, red blood cells,
and white blood cells were also performed on the same days.
For the determination of DB289 and DB75 plasma concen-
trations, blood samples were collected immediately before the
administration of the morning dose on days 1–5 (trough con-
centrations). Plasma concentrations were determined by liquid
chromatography/tandem mass spectrometry (LC/MS/MS) [7].
Briefly, DB289 and DB75 were extracted by a solid-phase ex-
traction procedure and reconstituted with 0.05% tetrafluoro
acetic acid in water and acetonitrile (90%/10% vol/vol). The
sample extracts were analyzed for DB289 and DB75 using LC/
MS/MS in the positive-ion multiple reaction monitoring mode.
DB2897-d8 and DB75-d8 were used as internal standards.
To distinguish between recrudescence and reinfection, par-
asites in enrollment and study blood samples were genotyped
by heteroduplex tracking assay using probes AF42 and AF63
designed to hybridize with the merozoite surface protein 1 gene
[8]. These probes distinguished 6 and 8 different genotypes,
respectively, in 14 blood samples obtained at enrollment and
in 2 blood samples obtained during the study (data not shown).
Results. A total of 32 patients were enrolled into the study
during a 3-month period. Nine patients (1 woman and 8 men),
with a mean age of 24.2 years (range, 18–30 years), had P. vivax
infections, and 23 patients (2 women and 21 men), with a mean
age of 26.9 years (range, 18–44 years), had P. falciparum in-
fections. The mean pretreatment parasite count was 2484 par-
asites/mL of blood (range, 1–16,350 parasites/mL of blood) for
patients with P. vivax infections and 1830 parasites/mL of blood
(range, 1–6610 parasites/mL of blood) for patients with P. falcip-
arum infections.
Mean trough plasma concentrations of DB289 and DB75 are
shown in figure 1. Plasma concentrations of DB75 increased
rapidly, and mean trough plasma concentrations appear to have
reached a maximum as early as day 2 of treatment (third dose
of DB289). DB75 plasma concentrations were well in excess of
DB289 plasma concentrations in all patients, and, on average,
the DB75:DB289 plasma concentration ratio was 140. DB75
plasma concentrations exceeded the target concentration of 5.85
mg/L of blood (i.e., the IC50 for the K1 [Thai] strain of P.
falciparum [9]) by the third dose of DB289 (morning of day
2), and trough plasma concentrations remained 4–5-fold higher
than the target concentration for 13 days.
DB289 was very well tolerated. All patients completed treat-
ment without interruptions in or adjustments to the dosing.
All adverse events noted were mild and self-resolved: 2 patients
had elevated ALT/AST levels (1 patient’s levels increased from
53/45 U/L to 97/209 U/L on day 14; 1 patient’s levels increased
from 19/19 U/L to 94/129 on day 28). One patient had an
elevation in amylase levels from 183 U/L at baseline to 575 U/
L on day 14. All 3 measurements returned to reference levels
without further treatment. No other adverse events that were
deemed to be related to treatment were noted.
All patients cleared parasites within 7 days of the initiation
of treatment with DB289. Overall, the parasitemean SD
clearance time (PCT) was h from the initiation of43 41
treatment, and the fever clearance time (FCT) wasmean SD
h from the initiation of treatment.18 22
All 9 patients with P. vivax infections cleared parasites within
7 days of the initiation of treatment with DB289 (table 1). The
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Figure 1. Mean (symbols) trough plasma concentrations of DB289 and DB75 and 95% confidence intervals (error bars) ( )np 32
Table 1. Clearance of Plasmodium species, relapses, recrudescence, and reinfection after treatment with DB289.
Parasite Treatment
Patients, no.
Total
Parasite clearance
in 7 days
P. vivax relapse
28 days
P. falciparum
recrudescence
28 days
Reinfection
28 days
P. vivax DB289, days 1–5; primaquine, days 10–23 9 9 1 0 0
P. falciparum DB289, days 1–5 23 23 3 1 1
PCT was h from the initiation of treat-mean SD 67 55
ment. The FCT was h from the initiationmean SD 18 29
of treatment. One patient had a recurrence of parasitemia caused
by P. vivax on day 9, before he was scheduled to receive prim-
aquine. This was presumed to be a relapse.
All 23 patients with P. falciparum infections cleared parasites
within 7 days of the initiation of treatment with DB289 (table
1). The PCT was h from the initiation ofmean SD 34 31
treatment. The FCT was h from the in-mean SD 18 20
itiation of treatment. Three of 23 patients had parasitemia
caused by P. vivax during the 28 days of follow-up, probably
because of a relapse from an undetected mixed infection. Two
of 23 patients with P. falciparum infections had recurrences of
parasitemia caused by P. falciparum: 1 on day 23 and 1 on day
28. Genotype analysis was performed by a heteroduplex track-
ing assay [8]. In the patient whose recurrence occurred on day
23, genetic identity was found in 2 of 2 probes, which suggested
that this patient had a recrudescence, and the patient was con-
servatively classified as having a treatment failure. In the patient
whose recurrence occurred on day 28, new bands were seen in
2 of 2 probes, which suggested that this patient had a reinfec-
tion. The latter patient could have become reinfected, because
he had returned home for 14 days. Thus, 22 of 23 patients with
P. falciparum infections were cured, for a cure rate of 96%.
Discussion. Most new antimalarial compounds that are in
development are derivatives of currently available drugs, and
their eventual deployment may be hampered by preexisting
cross-resistance. Thus, the in vivo efficacy of DB289 is impor-
tant, because this antimalarial compound is unrelated to any
existing one and could represent the prototype for an entirely
new class of antimalarial compounds.
Diamidines may have both novel transport pathways and
novel targets. These compounds appear to be transported into
P. falciparum–infected erythrocytes via a parasite-induced per-
meability pathway in the host cell membrane [10]. Possible
intracellular targets of diamidines include mitochondrial res-
piration [11], hemoglobin degradation [12], and DNA repli-
cation [13].
DB289 is also being developed for the treatment of human
African trypanosomiasis and P. jiroveci pneumonia under an
investigational new drug application from the US Food and
Drug Administration. Because the present study was the first
trial of DB289 in humans for the treatment of infections with
Plasmodium species, DB289 was given in the same regimen that
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had previously been administered to patients with human Af-
rican trypanosomiasis (2 doses per day for 5 days; P.Y., un-
published data). To avoid the development of drug resistance
[14], combination regimens, such as a 3-day combination reg-
imen of DB289 and artesunate, are being developed for use in
future studies.
DB289 demonstrated clear efficacy against P. falciparum, with
a 96% cure rate. Although all patients with P. vivax infections
cleared parasites, 1 patient who had this infection at enrollment
and 3 patients who had P. falciparum infections at enrollment
had recurrences. These events were likely the result of relapses
from patent or subpatent infections, but they could have been
the result of reinfections or drug failure. To distinguish between
these possibilities, further studies are needed.
The PCT for DB289 in patients with P. falciparum infections
appears to be quite low (mean, 34 h). Because some patients
who had extremely low levels of parasites were enrolled into
the study, a more precise determination of the PCT could be
obtained if it were calculated for patients who had higher levels
of parasites at enrollment. In the group of 11 patients who had
100 parasites/mL of blood at enrollment, the PCTmean SD
was h. In the group of 8 patients who had 100046.5 30.5
parasites/mL of blood at enrollment, the PCT wasmean SD
similar: h. This finding is consistent with the ob-49.0 28.1
servation that DB75 plasma concentrations exceeded the in vi-
tro IC50 for P. falciparum by the third dose of DB289 (morning
of day 2). Thus, the PCT may be longer than that found for
oral artesunate monotherapy (28–40 h) and possibly shorter
than that found for mefloquine monotherapy (63–82 h) in Thai
studies (reviewed in [15]).
The distribution and elimination of DB75 from patients were
characterized in a phase 2 trial of DB289 for the treatment of
early stage human African trypanosomiasis (P.Y., unpublished
data). Despite its relatively long terminal half-life, peak plasma
concentrations of DB75 on day 2 reached 75%–80% of steady-
state values. These data are consistent with the pharmacokinetic
and pharmacodyamic findings in the present study.
In summary, DB289 is a promising new antimalarial com-
pound that is orally active, safe, effective, and structurally novel.
Either DB289 or another one of the many second-generation
diamidine prodrugs currently being developed might become
an important addition to our antimalarial armamentarium.
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